Tennessee bill to bar PBM-owned pharmacies advances as CVS warns of closures

Tennessee's Senate Bill 2040 would bar pharmacy benefit managers (PBMs) from acquiring, holding, or controlling pharmacy licenses in the state, forcing PBM-affiliated pharmacies to divest or restructure by January 1, 2027. CVS Health warns the measure would eliminate access to 134 community pharmacies and close more than 25 MinuteClinic locations in Tennessee, citing lost access for specialty and chronic-care patients and potential job losses; proponents point to a 2024 state audit alleging CVS Caremark used spread pricing. The bill advances to the Senate Finance, Ways and Means Committee amid testimony from providers about care delays, and the initiative has related federal attention from Rep. Diana Harshbarger, signaling broader regulatory risk to PBM models.

Analysis

Market structure: Tennessee’s bill directly pressures vertically integrated PBM/retail combos (CVS [CVS] most exposed) but impacts only ~134 stores — roughly 1–2% of CVS retail footprint — so immediate revenue shock is limited. The bigger risk is precedent: if 5–10 additional states adopt similar rules over 12–36 months, PBM revenue mix (spread/rebate capture) could compress mid-single-digit percentage points, shifting share to independents and wholesalers (MCK, CAH, ABC).

Risk assessment: Near-term (days–weeks) headline risk is highest around House/Senate committee votes; expect 5–8% headline swings in CVS IV. Tail risks include a cascade of state laws or a federal ban that could shave 5–15% off PBM EBITDA over 2–4 years. Hidden dependencies: PBM earnings are driven by opaque rebate/spread mechanics — audits (like TN) can force contractual repricing with large payors, not just store divestitures.

Trade implications: Implement small, asymmetric hedges: use 3–6 month put spreads on CVS to capture legislative downside while funding cost; consider a 1–2% long position in wholesalers (MCK) as secular beneficiaries if independents win share. Avoid outright long positions in other vertically integrated PBMs (UNH, CI) until regulatory signal clarifies; consider pair trades (long MCK, short CVS) to isolate PBM/regulatory risk.

Contrarian angles: The market may overreact to Tennessee as a national existential threat — likelihood of wholesale closures is low given divestiture window through 2026–27, so binary downside is capped. If CVS pursues orderly divestitures, independent pharmacies could be acquisition targets and create M&A upside for regional players; trade this by selectively buying stressed regional pharmacy/specialty names on confirmed legislative passivity.

Key Decisions for Investors

• Establish a 1–2% portfolio hedge by buying a 3–6 month CVS (CVS) put spread: buy 10% OTM puts and sell 20% OTM puts, sized to cap cost; if Senate committee advances the bill within 30 days, increase to 2–3% hedge.
• Initiate a 1–2% long in McKesson (MCK) or Cardinal Health (CAH) as distributors likely to capture volume from independents; trim if CVS announces national divestiture plan or if premiums compress >5% QoQ.
• Open a pair trade: long 1% MCK (or CAH) / short 1% CVS to express regulatory-driven share shift; rebalance after the Senate Finance committee vote (expect decision window 30–90 days).
• If the bill passes committee or similar bills emerge in 2–3 additional states within 6 months, increase CVS downside exposure (add 6–12 month 15% OTM puts up to 2–3% portfolio) and reduce exposure to vertically integrated PBMs (UNH, CI) by 1–2% each.
• If no material legislative progress in 90 days, unwind option hedges (expect time decay) and redeploy proceeds into healthcare services names benefitting from better pharmacy margins (target 1–2% positions).